AR036554A1 - Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos - Google Patents

Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos

Info

Publication number
AR036554A1
AR036554A1 ARP020103525A ARP020103525A AR036554A1 AR 036554 A1 AR036554 A1 AR 036554A1 AR P020103525 A ARP020103525 A AR P020103525A AR P020103525 A ARP020103525 A AR P020103525A AR 036554 A1 AR036554 A1 AR 036554A1
Authority
AR
Argentina
Prior art keywords
formula
alkyl
alkenyl
compounds
preparation
Prior art date
Application number
ARP020103525A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR036554A1 publication Critical patent/AR036554A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de la fórmula (1) que son formados por el microorganismo Coniochaeta ellipsoidea Udagawa DSM 1385, o por uno de sus mutantes o variantes, durante la fermentación y que eventualmente son sometidos a la formación de derivados. La invención se refiere también a un procedimiento para la preparación de los compuestos de la fórmula (1) y a la utilización de los mismos como medicamento. Por otra parte, se refiere a la utilización de un compuesto de fórmula (5) para la preparación de un medicamento para el tratamiento y profilaxis de las neuropatías degenerativas o de la Enfermedad de Alzheimer. Reivindicación 1: Compuestos de la fórmula (1) en la cual R1 representa 1.0 -H, o: 2.0- un radical seleccionado de entre el grupo consistente en alquilo de C1-6, C2-6-alquenilo, C2-6-alquinilo o -C6-10-arilo, que pueden estar sustituidos uno o dos veces; 2.1.-OH, 2.2 =O, 2.3 -O-(C1-6-alquilo), 2.4 -O-(C2-6-alquenilo), 2.5 -(C6-10-arilo, 2.6 -NH-C1-6-alquilo, 2.7 -NH-C2-C6-alquenilo, 2.8-NH2, o 2.9 -flúor, cloro, bromo o yodo, pudiendo los sustituyentes 2,3 a 2.8 también estar adicionalmente sustituidos por funciones -CN, amida u oxima; 3.0.- -(C1-4-alquilo)-(C6-C10-arilo), o: 4.0.- -NH2, -NH-(C1-6-alquilo), -NH-(C2-6-alquenilo), R2 representa H, metilo, etilo, n-propilo, iso-propilo, n-butilo o iso-butilo; R3 representa un radical consistente en de 1 a 10 aminoácios, que puede tener una protección N-terminal; R4 representa H, alquilo de 1 a 6 átomos de carbono, -CO-(C1-6-alquilo), y p es un número entero igual a 0, 1 o 2; con la excepción de compuestos de la fórmula (1) en los cuales simultáneamente R1 representa H, R2, representa H, R3 representa -CO-CH3, R4 representa H, y p representa 0 o 1, y/o una forma estereoisómera del compuesto de la fórmula (1) y/o mezclas de dichas formas en cualquier proporción, y/o una sal fisiológicamente aceptable del compuesto de la fórmula (1). Reivindicación 20: Utilización de un compuesto de la formula (4) para la preparación de un medicamento para el tratamiento y profilaxis de las neuropatías degenerativas o de la Enfermedad de Alzheimer.
ARP020103525A 2001-09-22 2002-09-19 Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos AR036554A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10146737A DE10146737A1 (de) 2001-09-22 2001-09-22 Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR036554A1 true AR036554A1 (es) 2004-09-15

Family

ID=7699903

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103525A AR036554A1 (es) 2001-09-22 2002-09-19 Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos

Country Status (12)

Country Link
EP (2) EP1903033B1 (es)
JP (2) JP4287744B2 (es)
AR (1) AR036554A1 (es)
AT (2) ATE407942T1 (es)
AU (1) AU2002339519B2 (es)
CA (1) CA2461033C (es)
DE (3) DE10146737A1 (es)
ES (2) ES2314107T3 (es)
IL (2) IL160938A0 (es)
MX (1) MXPA04001951A (es)
PE (1) PE20030466A1 (es)
WO (1) WO2003029495A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056778A1 (en) * 2008-11-11 2010-05-20 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
JP7318948B2 (ja) * 2018-04-13 2023-08-01 国立大学法人京都大学 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2740454B1 (fr) * 1995-10-26 1997-11-21 Rhone Poulenc Rorer Sa Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
EP0941319A1 (fr) * 1996-11-08 1999-09-15 Aventis Pharma S.A. Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
BR0108247A (pt) * 2000-02-10 2002-11-05 Aventis Pharma Sa Composto, polipeptìdeo, ácido nucleico, vetor, vìrus recombinante defeituoso, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a triagem ou a caracterização de moléculas ativas e para a produção de um composto peptìdico
DE10060810A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Coniosetin und Derivate davon, Verfahren zur Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
PE20030466A1 (es) 2003-07-08
WO2003029495A3 (de) 2004-02-26
DE50212774D1 (de) 2008-10-23
JP4287744B2 (ja) 2009-07-01
EP1903033A1 (de) 2008-03-26
JP2009149662A (ja) 2009-07-09
ES2314107T3 (es) 2009-03-16
AU2002339519B2 (en) 2007-02-08
EP1474440B1 (de) 2008-09-10
IL160938A (en) 2010-11-30
CA2461033A1 (en) 2003-04-10
EP1903033B1 (de) 2009-04-29
IL160938A0 (en) 2004-08-31
EP1474440A2 (de) 2004-11-10
ATE430131T1 (de) 2009-05-15
MXPA04001951A (es) 2004-06-07
CA2461033C (en) 2011-12-06
DE10146737A1 (de) 2003-04-10
WO2003029495A2 (de) 2003-04-10
JP2005504131A (ja) 2005-02-10
ES2326563T3 (es) 2009-10-14
ATE407942T1 (de) 2008-09-15
DE50213512D1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
AU563683C (en) Substituted acyl derivative of 1,2,3,4-tetrahydroiso- quinoline-3-carboxylic acid
ATE174899T1 (de) Zytotoxische stilben-derivate und diese enthaltende pharmazeutische zusammensetzungen
GR3018319T3 (en) Pyran derivatives as inhibitors of 5-lipoxygenase.
HUT63838A (en) Process for producing 2-arylthiazole derivatives, pharmaceutically acdeptable salts thereof, as well as pharmaceutical compositions comprising such compounds
DK0412404T3 (da) Thiazolderivater, fremgangsmåder til fremstilling deraf og farmaceutiske præparater omfattende derivaterne
IL124563A (en) 5-phenyl-3-(substituted oximino) pyrrolo [3, 2-h] isoquinoline-2-one derivatives pharmaceutical compositions containing them and their preparation
DK162883D0 (da) N-glucosylerede carboxylsyreamidderivater, fremgangsmade til fremstilling heraf samt deres anvendelse til pavirkning af organismens egen forsvarsmekanisme
DE60141520D1 (de) 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
NO940523D0 (no) Nye pyrazin-derivater
SE8107273L (sv) 2-oxoazetidinderivat, sett att framstella democh anvendning derav
NO307464B1 (no) Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter
ES8404361A1 (es) Un procedimiento para la preparacion de un derivado de cefalosporina.
AR036554A1 (es) Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos
ATE212637T1 (de) Anitbiotisch wirksame cephalosporine und verfahren zu ihrer herstellung
JPS5455047A (en) Vinyl chloride resin composition
GB1473981A (en) Hydrazino-cephalosporanic acid derivatives
EP0802179A4 (en) DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER
FR2242986B1 (es)
ES2092470T3 (es) Derivados de pirrolidina.
BRPI0411057A (pt) análogos de prostaglandina e de piperidinila
SE8403168L (sv) Karboxylsyraamidforeningar och derivat derav
ES2052058T3 (es) Composiciones agricolas y horticolas que confieren resistencia a las plantas contra las tensiones producidas por la sal y el agua.
FI922518A (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
FA Abandonment or withdrawal